Inside the research

Amphastar Pharmaceuticals, Inc.

AMPH Research profile · latest available data

Price overview

$26.13

▼ -0.14 (-0.5%)

52w hi$29.40
52w lo$16.87
Vol376.90K
As of25 Sep 2026

The Verdict

Hold

Our score +0.25

Short+0.10
Medium+0.35
Long+0.33

computed 2026-09-27

Key fundamentals

Amphastar Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Market cap$1.11B
Enterprise value$1.51B
Trailing P/E15.46x
Forward P/E8.21x
EV / EBITDA7.76x
P / S (ttm)1.52x
Profit margin10.8%
Return on equity10.3%
Revenue growth+5.4%
Earnings growth+4.7%
Debt / equity89.61

Layer Breakdown

LayerRawContribution
Fundamental+0.25
Sector+0.08
Technical+0.10
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

United States · www.amphastar.com

Risk Metrics

Beta vs SPX0.62
Corr SPX0.21
Annual vol47.3%
Annual ret-20.0%
Sharpe-0.42
Max DD-68.4%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$26.43
High / Low$30.00 / $22.00
Median$25.00
Analysts7
Strong Buy1
Buy1
Hold5
Sell0
Strong Sell0

Recent rating actions

2026-05-08Needham→ Hold
2026-04-21Jefferies→ Hold
2026-04-08Barclays→ Equal-Weight
2026-02-27Wells Fargo→ Overweight
2026-02-27Needham→ Buy
2025-12-09Barclays→ Equal-Weight

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-07-13Officer / Director Changeread
2026-07-08Other Material Eventread
2026-06-03Shareholder Voteread
2026-05-07Earnings Release, Exhibitsread
2026-03-16Other Material Eventread
2026-03-06Officer / Director Change, Exhibitsread
2026-03-06Material Agreement, Exhibitsread
2026-02-26Earnings Release, Exhibitsread
2026-01-12Material Agreement, Reg FD Disclosure…read
2025-11-06Earnings Release, Exhibitsread
2025-10-24Material Agreementread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-11PRINS RICHARD KDirectorSell7.97K$161.85K
2026-08-07PETERS WILLIAM JDirector, Officer, CFO, EOption exercise5.05K$100.00K
2026-08-07PETERS WILLIAM JDirector, Officer, CFO, ESell8.18K$183.89K
2026-07-09Pierce Anthony TDirectorGrant7.89K—
2026-06-02Lee HowardDirectorWithheld for tax769$14.19K
2026-06-01Lee HowardDirectorGrant8.14K—
2026-06-01PRINS RICHARD KDirectorGrant8.14K—
2026-06-01Gaugh David RussellDirectorGrant8.14K—
2026-06-01Deflin GayleDirectorGrant8.14K—
2026-06-01ZASLOFF MICHAEL ADirectorGrant8.14K—

Flow & Concentration

Insider 180d net-$345.74K
Insider buys / sells0 / 2
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-124view
2026-08-114view
2026-08-0610-Qview
2026-08-068-Kview
2026-07-138-Kview
2026-07-133view
2026-07-134view
2026-07-088-Kview
2026-06-034view
2026-06-034view
2026-06-034view
2026-06-034view
2026-06-034view
2026-06-038-Kview
2026-06-034view

The Long Run

FY 2014–2025 · 12 years

LineLatestCAGRTrend
Revenue$644.39M+24.2%
Gross profit$356.06M+19.3%
Operating income$196.99M+29.2%
Net income$159.52M+68.2%
Cash from ops$156.12M+39.8%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$26.25$26.63$25.66$26.13376.90K
Sep 24$24.81$26.31$24.65$26.27572.10K
Sep 23$24.39$25.12$24.20$24.96508.10K
Sep 22$24.60$24.83$24.00$24.32522.40K
Sep 21$23.54$25.41$23.45$24.48595.80K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →